Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis. Tasset I, Bahamonde C, Agüera E, Conde C, Cruz AH, Pérez-Herrera A, Gascón F, Giraldo AI, Ruiz MC, Lillo R, et al. Pharmacol Rep. 2013; 65(3):634-1. PMID: 23950585. Abstract CommentRecommendBookmarkWatch